Novo looks to expand label for diabetes drug
Novo Nordisk hopes to convince the European Medicines Agency to green-light an expanded label for one of its diabetes drugs.
BY BENJAMIN WERNER CHRISTENSEN
If Novo Nordisk has its way, the label for its diabetes drug Levemir will soon be changed to include an extended indication, the agenda for a meeting of EMA’s Committee for medicinal products for human use (CHMP) shows.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo launches new drug
For abonnenter
Nordea: Novo’s revenue will increase markedly
For abonnenter
Here is how much Novo has made with Rebien at the helm
For abonnenter
